Skip to main content
Erschienen in: International Journal of Clinical Oncology 1/2018

Open Access 25.07.2017 | Original Article

Impact of major different variants of papillary thyroid microcarcinoma on the clinicopathological characteristics: the study of 1041 cases

verfasst von: Jingtai Zhi, Jingzhu Zhao, Ming Gao, Yi Pan, Jianghua Wu, Yigong Li, Dapeng Li, Yang Yu, Xiangqian Zheng

Erschienen in: International Journal of Clinical Oncology | Ausgabe 1/2018

Abstract

Background

The incidence of papillary thyroid microcarcinoma (PTMC) has been increasing globally in the past few decades. PTMC does not have a distinctive morphology that results in differences in biological behavior. The aim of this study was to classify PTMCs according to the morphological features and explore the relationship with clinicopathological characteristics. Additionally, we sought to evaluate whether different variants of PTMC can be an independent predictor for lymph mode metastasis when considering other risk factors.

Methods

Between December 2014 and December 2015, 1041 PTMC cases undergoing surgical resection at Tianjin Medical University Cancer Institute and Hospital were reviewed retrospectively. Statistical analysis was performed to investigate the independent factors for lymph node metastasis in PTMC.

Results

Conventional variant PTMC (CPTMC), follicular variant PTMC (FPTMC), and encapsulated variant PTMC (EnPTMC) were major variants in PTMC, collectively accounting for 96.7% of the entire PTMC cohort.There were significant differences in clinicopathological characteristics among the three major variants. The frequency of aggressive parameters was significantly different among the three variants, including tumor size, minimal extrathyroidal extension (minimal ETE), and lymph node metastasis (all P < 0.05), being highest in CPTMC, lowest in EnPTMC, and intermediate in FPTMC. FPTMC (OR = 0.642, P = 0.003) and EnPTMC (OR = 0.540, P = 0.041) were independent protective factors for lymph node metastasis (LNM). In contrast, male gender (OR = 1.836, P = 0.000), age less than 45 years (OR = 1.457, P = 0.009), tumor size greater than 0.5 cm (OR = 1.453, P = 0.007), calcification (OR = 1.465, P = 0.016), minimal ETE (OR = 1.801, P = 0.001), and multifocality (OR = 1.721, P = 0.000) were independent risk factors for LNM.

Conclusions

The present study demonstrates the distinct biological behaviors of the three major PTMC variants and establishes an aggressive order of CPTMC ≫ FPTMC > EnPTMC. It is necessary to take into consideration variant-related risks and other independent predictors for the determination of lymphadenectomy in patients with PTMC.
Hinweise
Jingtai Zhi and Jingzhu Zhao contributed equally and should be considered joint first authors.
Abkürzungen
PTMC
Papillary thyroid microcarcinoma
PTC
Papillary thyroid carcinoma
FNAB
Fine-needle aspiration biopsy
LNM
Lymph node metastasis
Minimal ETE
Minimal extrathyroidal extension
HT
Hashimoto’s thyroiditis
CPTMC
Conventional variant PTMC
FPTMC
Follicular variant PTMC
EnPTMC
Encapsulated variant PTMC
E-FPTC
Encapsulated follicular variant of PTC
E-CPTC
Encapsulated conventional variant of PTC

Introduction

Papillary thyroid microcarcinoma (PTMC), defined as papillary thyroid carcinoma (PTC) 10 mm or less in diameter, has been dramatically rising in incidence during the past few decades, accounting for nearly half the increase in PTC [14]. PTMC is generally regarded as an indolent disease but does pose a risk for local recurrence and distant metastasis [5, 6]. Identification of aggressive cases from favorable ones is necessary for the patient-tailored treatment of PTMC.
PTMC does not have a distinctive morphology, which means that all cellular features and growth patterns that can be found in other variants of PTC can be observed in PTMC [7, 8]. In PTC, the variant-related differences in biological behavior and prognosis are very large. Compared with the conventional variant, solid variant, diffuse sclerosing variant, and tall cell variant are recommended as the aggressive types, and follicular variant and the Warthin-like variant are considered favorable [914], which has further led to variant-related changes in PTC treatment [11, 13, 15, 16]. Considering the findings of these studies, the appearance of other variants in PTMC may incur variant-relevant risk, which has a profound impact on the treatment strategies. The purpose of this study was to classify the PTMCs according to the nature of the tumor boundaries, distinct architecture, or cellular characteristics and explore the clinicopathological characteristics of different variants of PTMC. Additionally, we sought to evaluate whether different variants of PTMC can be an independent predictor for lymph mode metastasis when considering other risk factors.

Materials and methods

This retrospective cohort review research was supported by the academic ethics board, and informed consent was obtained from all patients to allow their information to be used for the study.

Patients

We consecutively collected 1041 patients from all the PTMC cases between December 2014 and December 2015 in our hospital. Exclusion criteria were (1) patients had other malignancy, (2) no lymph node was resected, (3) distant metastasis, (4) patients with a history of previous operation for PTC, (5) largest tumor greater than 1 cm, and (6) age less than 18 years. All cases were grouped according to the subtype of the largest tumor. These chosen patients were mostly asymptomatic, and their lesions were accidently discovered during the annual physical examination. Once the nodules were suspected for malignancy by fine-needle aspiration biopsy (FNAB) or ultrasound (US), either thyroid lobectomy or total/near total thyroidectomy combined with prophylactic central neck dissection was performed in all patients. Patients who had preoperatively or intraoperatively proven lateral neck metastasis by FNAB or biopsy underwent therapeutic lateral neck dissection.

Pathological examination

Both intraoperative frozen and postoperative paraffin sections were submitted to two experienced endocrine pathologists (Yi Pan and Jianghua Wu) to establish the diagnosis of PTMC and other characteristic pathological parameters, including histopathological types, multifocality, coexistence of Hashimoto’s thyroiditis (HT), minimal extrathyroidal extension (minimal ETE), status of lymph node metastasis (LNM), and tumor size, fibrosis, and calcification of the largest tumor. All the pathological parameters were identified according to Rosai and Ackerman’s surgical pathology, 10th edition. Representative sections were examined in a blinded fashion, and the concordance rate was 97%. The final diagnoses of discordant or rare-variant cases were based on the consensus of two pathologists.

Statistical analysis

Differences among variants were compared by the chi-square test. Univariate and multivariate logistic regression models were used to evaluate independent predictors for lymph mode metastasis in PTMC. P < 0.05 was assumed as statistical significance. SPSS version 22.0.0 (IBM, Armonk, NY, USA) was used to perform the statistical analysis.

Results

There were 1041 PTMC patients enrolled in this study. The major variants of PTMC, including conventional variant (CPTMC, 471 cases, 45.2%; Fig. 1a), follicular variant (FPTMC, 454 cases, 43.6%; Fig. 1b), and encapsulated variant (EnPTMC, 82 cases, 7.9%; Fig. 1c), collectively accounted for 96.7% of the entire PTMC cohort. Other variants of PTMC (e.g., Warthin-like variant, solid variant, oncocytic variant, tall cell variant, or trabecular variant) were rare (collectively, 34 cases, 3.3%), so we only analyzed the clinicopathological characteristics of the 1007 cases with the major variants. The sex ratio was 1:3.86 (male:female, 207:800). The age range was 18–73 (mean, 46 ± 9.5) years. The size of the largest tumor was 5.7 ± 1.8 (mean ± SD) mm. The rate of fibrosis and calcification was 98.5% and 31.7%, respectively. Multifocal tumors were found in 364 cases (Table 1). Minimal ETE was seen in 200 (19.9%) patients, including 59 in vascular, 120 in fat, 8 in striated muscle, 1 in nerve, and 12 multiple minimal ETE. HT was present in 26.3% of the patients. The frequency of LNM was 26.3%; among these, 275 were N1a and 40 were N1b (Table 2). Most patients (94.6%) underwent prophylactic central neck dissection; in only 54 patients was central + lateral neck dissection performed.
Table 1
Distribution of variants among 1041 patients between December 2014 and December 2015
Subtype
N
Present
Conventional
471
45.2
Follicular
454
43.6
Encapsulated
82
7.9
Warthin-like
17
1.6
Solid
3
0.3
Oncocytic
3
0.3
Tall cell
6
0.6
Trabecular
5
0.5
Table 2
Clinicopathological characteristics of patients with three major variants of papillary thyroid microcarcinoma (PTMC)
Characteristics
N (mean ± SD)
Present
Gender
 Female
800
79.4
 Male
207
20.6
Age (years)
46 ± 9.5
 
 ≥45
558
55.4
 <45
449
44.6
Tumor size
0.57 ± 0.18
 
 >5 mm
510
50.6
 ≤5 mm
497
49.4
Fibrosis
 Absent
15
1.5
 Present
992
98.5
Calcification
 Absent
688
68.3
 Present
319
31.7
Minimal ETE
 Absent
807
80.1
 Present
200
19.9
 Vascular
59
5.9
 Fat
120
11.9
 Striated muscle
8
0.8
 Nerve
1
0.1
 Multiple MEE
12
1.2
Coexistence of HT
 Absent
742
73.7
 Present
265
26.3
Multifocality
 Absent
643
63.9
 Present
364
36.1
Lymph node metastases
 Absent
692
68.7
 Present
315
31.3
N-stage
 N0
692
68.7
 N1a
275
27.3
 N1b
40
4.0
Neck excision extent
 Central
953
94.6
 Central + lateral
54
5.4
Minimal ETE minimal extrathyroidal extension, HT Hashimoto’s thyroiditis, LNM lymph node metastases

Comparison of the clinicopathological data among three variants of PTMC

Comparisons of the clinicopathological features of the three PTMC variants are summarized in Table 3. Age, calcification, MEE, tumor size, and LNM showed significant differences among three variant-specific groups. The aggressive parameters, including MEE, tumor size, and lymph node metastasis, were highest in CPTMC, lowest in EnPTMC, and generally intermediate in FPTMC. In contrast with this order, the prevalence of age of 45 years or more and calcification was highest in EnPTMC, lowest in CPTMC, and generally intermediate in FPTMC. These patterns were further confirmed on pair-wise comparison (Table 4). Specifically, the prevalence of patient age of 45 years or more was similar between FPTMC and EnPTMC and significantly less common in CPTMC. The rate of calcification was similar between CPTMC and FPTMC and significantly higher in EnPTMC. Tumor size was similar between FPTMC and EnPTMC, and both were smaller than CPTMC. The incidence of minimal ETE showed no difference between CPTMC and FPTMC, but minimal ETE was significantly less commonly seen in EnPTMC than in CPTMC and FPTMC. The occurrence of LNM was significantly higher in CPTMC than in FPTMC and EnPTMC.
Table 3
Comparison of the clinicopathological data among three variants of PTMC
Characteristic
CPTMC
FPTMC
EnPTMC
χ 2
P
Gender
  
 Female
360 (76.4%)
373 (82.2%)
67 (81.7%)
4.920
0.085
 Male
111 (23.6%)
81 (17.8%)
15 (18.3%)
  
Age (years)
  
 ≥45
239 (50.7%)
263 (57.9%)
56 (68.3%)
10.827
0.004
 <45
232 (49.3%)
191 (42.1%)
26 (31.7%)
  
Fibrosis
  
 Absent
11 (2.3%)
4 (0.9%)
0 (0.0%)
4.682
0.096
 Present
460 (97.7%)
450 (99.1%)
82 (100%)
  
Calcification
  
 Absent
351 (74.5%)
308 (67.8%)
29 (35.4%)
49.564
<0.001
 Present
120 (25.5%)
146 (32.2%)
53 (64.6%)
  
Minimal ETE
  
 Absent
370 (78.6%)
355 (78.2%)
82 (100%)
22.143
<0.001
 Present
101 (21.4%)
99 (21.8%)
0 (0.0%)
  
Coexistence of HT
  
 Absent
339 (72.0%)
344 (75.8%)
59 (72.0%)
1.857
0.395
 Present
132 (28.0%)
110 (24.2%)
23 (28.0%)
  
Multifocality
  
 Absent
302 (64.1%)
285 (62.8%)
56 (68.3%)
0.943
0.624
 Present
169 (35.9%)
169 (37.2%)
26 (31.7%)
  
Tumor size
  
 >5 mm
272 (57.7%)
204 (44.9%)
34 (41.5%)
18.200
<0.001
 ≤5 mm
199 (42.3%)
250(55.1%)
48 (58.5%)
  
LNM
  
 Absent
296 (62.8%)
332 (73.1%)
64 (78.0%)
14.986
0.001
 Present
175 (37.2%)
122 (26.9%)
18 (22.0%)
  
CPTMC conventional variant PTMC, FPTMC follicular variant PTMC, EnPTMC encapsulated variant PTMC, minimal ETE minimal extrathyroidal extension, HT Hashimoto’s thyroiditis, LNM lymph node metastases
Table 4
Pairwise comparison of clinicopathological features among three variants of PTMC
Characteristic
CPTMC versus FPTMC
FPTMC versus EnPTMC
EnPTMC versus CPTMC
Age
0.028
0.078
0.003
Calcification
0.025
<0.001
<0.001
Minimal ETE
0.894
<0.001
<0.001
Tumor size
<0.001
0.560
0.006
LNM
0.001
0.351
0.008
CPTMC conventional variant PTMC, FPTMC follicular variant PTMC, EnPTMC encapsulated variant PTMC, minimal ETE minimal extra-thyroidal extension, HT Hashimoto’s thyroiditis, LNM lymph node metastases

Correlation between clinicopathological features and LNM

Univariate logistic regression analysis indicated that gender, age, subtypes, MEE, multifocality, and tumor size were all strongly associated with the LNM in PTMC (P < 0.05). There was a significant difference in the occurrence of LNM between CPTMC with calcification and without calcification. In the other two subtypes, however, calcification was not remarkably correlated with incidence of LNM. Multiple logistic regression analysis indicated that male gender (OR, 1.896; 95% CI, 1.355–2.651), age45 years or less (OR, 1.393; 95% CI, 1.053–1.842), tumor size (OR, 1.453; 95% CI, 1.068–1.977), minimal ETE (OR, 1.801; 95% CI, 1.257–2.579), and multifocality (OR, 1.530; 95% CI, 1.129–2.074) were all significantly connected with the LNM in PTMC (P < 0.05). Compared with CPTMC, FPTMC showed significant differences (P = 0.006), which means that FPTMC (OR, 0.660; 95% CI, 0.492–0.885) was an independent protective factor for LNM. Although the P value >0.05, the OR of EnPTMC was 0.625, also indicating the indolent nature of EnPTMC (Table 5).
Table 5
Univariate analysis of lymph node metastasis and clinicopathological features in PTMC
Characteristic
LNM−
LNM+
χ 2
P
Gender
 
 Female
573
227
15.289
<0.001
 Male
119
88
  
Age (years)
 
 ≥45
406
152
9.506
0.002
 <45
286
163
  
Subtypes
 
 CPTMC
296
175
14.986
0.001
 FPTMC
332
122
  
 EnPTMC
64
18
  
Fibrosis
 
 Absent
9
6
0.538
0.463
 Present
683
309
  
Calcification
 
 CPTMC
 
  Absent
232
119
6.239
0.012
  Present
64
56
  
 FPTMC
 
  Absent
232
76
2.352
0.125
  Present
100
46
  
EnPTMC
 
 Absent
24
5
0.581
0.446
 Present
40
13
  
Minimal ETE
 
 Absent
585
222
26.890
0.000
 Present
107
93
  
Coexistence of HT
 
 Absent
505
237
0.571
0.450
 Present
187
78
  
Multifocality
 
 Absent
474
169
20.671
0.000
 Present
218
146
  
Tumor size
 
 >5 mm
311
199
28.788
0.000
 ≤5 mm
381
116
  
CPTMC conventional variant PTMC, FPTMC follicular variant PTMC, EnPTMC encapsulated variant PTMC, minimal ETE minimal extrathyroidal extension, HT Hashimoto’s thyroiditis, LNM lymph node metastases

Discussion

The American Thyroid Association (ATA) guidelines recommend thyroidectomy without prophylactic central neck dissection is appropriate for small (T1 or T2), noninvasive, clinically node-negative (cN0) PTC [15]. In cases whose largest tumor is >10 mm, this practice successfully keeps the balance of the risk caused by the enlarged surgery extent and the benefit of reduction in recurrence. In PTMC, however, the balance is remarkably disturbed by variant-specific differences without sufficient attention. Although PTMC is a subset of PTC, variants of PTMC differ from those of PTC in two respects: clinicopathological features and variant distribution, resulting in an unbalanced extent of surgery in PTMC patients (Table 6).
Table 6
Multivariate analysis of lymph node metastasis and clinicopathological features in PTMC
Characteristics
B
SE
Wald
P
OR
95% CI
Lower
Upper
Gender
0.640
0.171
13.964
0.000
1.896
1.355
2.651
Age
−0.331
0.143
5.381
0.020
1.393
1.053
1.842
Subtypes
       
 CPTMC
  
8.681
0.013
Reference
  
 FPTMC
−0.415
0.150
7.687
0.006
0.660
0.492
0.885
 EnPTMC
−0.469
0.296
2.522
0.112
0.625
0.350
1.116
Tumor size
0.426
0.155
7.527
0.06
1.530
1.129
2.074
Fibrosis
−0.327
0.549
0.356
0.551
0.721
0.246
2.112
Minimal ETE
0.581
0.182
10.153
0.001
1.788
1.251
2.557
Coexistence of HT
−0.060
0.166
0.130
0.719
0.942
0.680
1.305
Multifocality
0.537
0.147
13.282
0.000
1.712
1.282
2.285
Constant
−1.400
0.644
4.725
0.030
0.247
  
CPTMC conventional variant PTMC, FPTMC follicular variant PTMC, EnPTMC encapsulated variant PTMC, minimal ETE minimal extrathyroidal extension, HT Hashimoto’s thyroiditis
Encapsulated variant is defined as a papillary carcinoma totally surrounded by a capsule. In the present study, EnPTMC showed excellent biological behavior, being the lowest in aggressive parameters (tumor size and incidence of minimal ETE and LNM) among three variants. Because several authors have reported that age less than 45 years had a higher incidence of lymph node metastasis [17, 18], the age distribution also indicated the indolent nature of EnPTMC. The previous studies of PTC grouped the encapsulated variant according to the variant inside, underlining the benign behavior of the encapsulated follicular variant of PTC (E-FPTC) [19, 20]. One study reported that E-FPTC resembled the adenoma/follicular carcinoma group of tumors in its capsular/vascular invasive pattern and its propensity for lymph node metastasis whereas E-CPTC behaved more like conventional PTC [21]. In 2016, E-FPTC was categorized as low risk by the ATA [15]. In the present study, however, there was no significant difference in any respect between the encapsulated conventional variant of PTMC (E-CPTMC) and the encapsulated follicular variant of PTMC (not shown in the table), and both were shown as indolent. Overtreatment may occur in patients with EnPTMC (especially E-CPTMC), which needs further studies to determine the optimal extent of surgery.
Follicular variant is defined as a papillary carcinoma composed entirely or almost entirely of follicles. FPTMC was entirely intermediate in all parameters between CPTMC and EnPTMC. Except for the incidence of minimal ETE, all the aggressive parameters including age, tumor size distribution, and the occurrence rate of LNM in FPTMC was analogous to that of EnPTMC, remarkably differentiated from that of CPTMC. These findings are supported by the previous studies on PTC [9, 22]. In the present study, FPTMC accounted for 43.6% of the 1041 PTMCs, whose prevalence was nearly equal to that of CPTMC. This finding was particularly worth noting because several reports mentioned that the incidence of CPTC was 2 to 4.5 times higher than that of FPTC [9, 23, 24]. One reasonable hypothesis for the decrease in proportion of follicular variant from PTMC to PTC is that, compared with CPTMCs, fewer FPTMCs enlarge in tumor size and develop into FPTC. In spite of the absence of relevant evidence, this hypothesis may have some association with the phenomenon that quite a number of PTMCs enlarged slowly or almost did not enlarge [25, 26]. In our study, the size of tumor was significantly smaller in FPTMCs than in CPTMCs (44.9% vs. 55.7%, P < 0.001). The change in variant distribution indicates the specific growth pattern on FPTMC, deserving further studies and cautious selection in surgery extent.
In our univariate and multivariate analysis, LNM was significantly associated with male gender, age less than 45 years, tumor size, minimal ETE, and multifocality, which was supported by the recent study [6, 27, 28]. Compared with CPTMC, FPTMC was an independent protective factor for LNM, again demonstrating the indolent nature of this variant.
Calcification has been reported as a significant indicator for nonprogressive disease in PTMC [29], which was in contrast to our findings. In CPTMC, calcification was positively correlated with LNM, whereas in FPTMC and EnPTMC, no significant differences in LNM were found between tumors with or without calcification. Calcification in both subtypes was correlated with the unknown growth pattern but not with the occurrence of LNM. A cautious extent of surgery should be selected whether or not calcification is observed.
To investigate whether subtypes can be confirmed intraoperatively, differences in variant identification were compared between intraoperative frozen sections and postoperative paraffin sections. In intraoperative frozen sections, all the variants, except for the oncocytic variant, can be identified correctly according to the distinctive morphological characters, meaning that for almost all PTMCs, variants can be confirmed intraoperatively and thus used for the decision as to surgery extent.
There are three limitations in the present study. To clarify whether cases had LNM, we excluded the cases with no lymph node resected, which led to a slight rise in the rate of LNM. This issue was minimized by the rare occurrence of this situation. Also, the lower rate of LNM indicated that use of lymphadenectomy should be cautious in PTMC. The effect of surgery extent on data was another issue, being minimized by preoperative US of every patient. Because of color aberration, the oncocytic variant may be confused with other variants in frozen sections. As this variant does not have any prognostic implications in PTC [8] and was rare in PTMC, this limitation may not be important.

Conclusion

The present study establishes the three major variants in PTMC and their aggressive order: CPTMC ≫ FPTMC > EnPTMC. For reasons of distinct clinicopathological features and variant distribution, variant identification has important clinical significance in determination of lymphadenectomy, having an effect on individual treatments in PTMC. Patients with variant-relevant risk and other predictors, including male gender, age less than 45 years, tumor size, minimal ETE, calcification, and multifocality, are recommended to undergo prophylactic lymph node dissection.

Acknowledgments

This work was partially supported by grants from National Natural Science Foundation of China (Grant Nos. 81402392, 81502322, 81472580, 81272282) and Tianjin Municipal Science and technology project (Grant No. 15JCQNJC12800).

Compliance with ethical standards

Conflict of interest

The authors declare no conflict of interest.
Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://​creativecommons.​org/​licenses/​by/​4.​0/​), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made.

Unsere Produktempfehlungen

e.Med Interdisziplinär

Kombi-Abonnement

Für Ihren Erfolg in Klinik und Praxis - Die beste Hilfe in Ihrem Arbeitsalltag

Mit e.Med Interdisziplinär erhalten Sie Zugang zu allen CME-Fortbildungen und Fachzeitschriften auf SpringerMedizin.de.

Literatur
2.
4.
Zurück zum Zitat Jung CK, Little MP, Lubin JH et al (2014) The increase in thyroid cancer incidence during the last four decades is accompanied by a high frequency of BRAF mutations and a sharp increase in RAS mutations. J Clin Endocrinol Metab 99(2):E276–E285. doi:10.1210/jc.2013-2503 CrossRefPubMed Jung CK, Little MP, Lubin JH et al (2014) The increase in thyroid cancer incidence during the last four decades is accompanied by a high frequency of BRAF mutations and a sharp increase in RAS mutations. J Clin Endocrinol Metab 99(2):E276–E285. doi:10.​1210/​jc.​2013-2503 CrossRefPubMed
5.
Zurück zum Zitat Pedrazzini L, Baroli A, Marzoli L et al (2013) Cancer recurrence in papillary thyroid microcarcinoma: a multivariate analysis on 231 patients with a 12-year follow-up. Minerva Endocrinol 38(3):269–279PubMed Pedrazzini L, Baroli A, Marzoli L et al (2013) Cancer recurrence in papillary thyroid microcarcinoma: a multivariate analysis on 231 patients with a 12-year follow-up. Minerva Endocrinol 38(3):269–279PubMed
10.
Zurück zum Zitat Jun HH, Kim SM, Hong SW et al (2014) Warthin-like variant of papillary thyroid carcinoma: single institution experience. ANZ J Surg. doi:10.1111/ans.12725 Jun HH, Kim SM, Hong SW et al (2014) Warthin-like variant of papillary thyroid carcinoma: single institution experience. ANZ J Surg. doi:10.​1111/​ans.​12725
11.
12.
Zurück zum Zitat Moreno A, Rodriguez JM, Sola J et al (1996) Encapsulated papillary neoplasm of the thyroid: retrospective clinicopathological study with long term follow up. Eur J Surg Acta Chir 162(3):177–180 Moreno A, Rodriguez JM, Sola J et al (1996) Encapsulated papillary neoplasm of the thyroid: retrospective clinicopathological study with long term follow up. Eur J Surg Acta Chir 162(3):177–180
13.
Zurück zum Zitat Lam AK, Lo CY, Lam KS (2005) Papillary carcinoma of thyroid: a 30-yr clinicopathological review of the histological variants. Endocr Pathol 16(4):323–330CrossRefPubMed Lam AK, Lo CY, Lam KS (2005) Papillary carcinoma of thyroid: a 30-yr clinicopathological review of the histological variants. Endocr Pathol 16(4):323–330CrossRefPubMed
14.
Zurück zum Zitat Nikiforov YE, Erickson LA, Nikiforova MN et al (2001) Solid variant of papillary thyroid carcinoma: incidence, clinical–pathologic characteristics, molecular analysis, and biologic behavior. Am J Surg Pathol 25(12):1478–1484CrossRefPubMed Nikiforov YE, Erickson LA, Nikiforova MN et al (2001) Solid variant of papillary thyroid carcinoma: incidence, clinical–pathologic characteristics, molecular analysis, and biologic behavior. Am J Surg Pathol 25(12):1478–1484CrossRefPubMed
15.
Zurück zum Zitat Haugen BR, Alexander EK, Bible KC et al (2016) 2015 American Thyroid Association management guidelines for adult patients with thyroid nodules and differentiated thyroid cancer: The American Thyroid Association guidelines task force on thyroid nodules and differentiated thyroid cancer. Thyroid 26(1):1–133. doi:10.1089/thy.2015.0020 CrossRefPubMedPubMedCentral Haugen BR, Alexander EK, Bible KC et al (2016) 2015 American Thyroid Association management guidelines for adult patients with thyroid nodules and differentiated thyroid cancer: The American Thyroid Association guidelines task force on thyroid nodules and differentiated thyroid cancer. Thyroid 26(1):1–133. doi:10.​1089/​thy.​2015.​0020 CrossRefPubMedPubMedCentral
17.
Zurück zum Zitat Liu LS, Liang J, Li JH et al (2016) The incidence and risk factors for central lymph node metastasis in cN0 papillary thyroid microcarcinoma: a meta-analysis. Eur Arch Oto-Rhino-Laryngol. doi: 10.1007/s00405-016-4302-0 Liu LS, Liang J, Li JH et al (2016) The incidence and risk factors for central lymph node metastasis in cN0 papillary thyroid microcarcinoma: a meta-analysis. Eur Arch Oto-Rhino-Laryngol. doi: 10.​1007/​s00405-016-4302-0
18.
Zurück zum Zitat Zhang L, Yang J, Sun Q et al (2016) Risk factors for lymph node metastasis in papillary thyroid microcarcinoma: older patients with fewer lymph node metastases. Eur J Surg Oncol 42(10):1478–1482. doi: 10.1016/j.ejso.2016.07.002 Zhang L, Yang J, Sun Q et al (2016) Risk factors for lymph node metastasis in papillary thyroid microcarcinoma: older patients with fewer lymph node metastases. Eur J Surg Oncol 42(10):1478–1482. doi: 10.​1016/​j.​ejso.​2016.​07.​002
19.
Zurück zum Zitat Thompson LD (2016) Ninety-four cases of encapsulated follicular variant of papillary thyroid carcinoma: a name change to Noninvasive Follicular Thyroid Neoplasm with Papillary-like Nuclear Features would help prevent overtreatment. Mod Pathol 29(7):698–707. doi:10.1038/modpathol.2016.65 CrossRefPubMed Thompson LD (2016) Ninety-four cases of encapsulated follicular variant of papillary thyroid carcinoma: a name change to Noninvasive Follicular Thyroid Neoplasm with Papillary-like Nuclear Features would help prevent overtreatment. Mod Pathol 29(7):698–707. doi:10.​1038/​modpathol.​2016.​65 CrossRefPubMed
21.
Zurück zum Zitat Rivera M, Tuttle RM, Patel S et al (2009) Encapsulated papillary thyroid carcinoma: a clinico-pathologic study of 106 cases with emphasis on its morphologic subtypes (histologic growth pattern). Thyroid 19(2):119–127. doi:10.1089/thy.2008.0303 CrossRefPubMed Rivera M, Tuttle RM, Patel S et al (2009) Encapsulated papillary thyroid carcinoma: a clinico-pathologic study of 106 cases with emphasis on its morphologic subtypes (histologic growth pattern). Thyroid 19(2):119–127. doi:10.​1089/​thy.​2008.​0303 CrossRefPubMed
22.
Zurück zum Zitat Tunca F, Sormaz IC, Iscan Y et al (2015) Comparison of histopathological features and prognosis of classical and follicular variant papillary thyroid carcinoma. J Endocrinol Invest 38(12):1327–1334. doi:10.1007/s40618-015-0376-6 CrossRefPubMed Tunca F, Sormaz IC, Iscan Y et al (2015) Comparison of histopathological features and prognosis of classical and follicular variant papillary thyroid carcinoma. J Endocrinol Invest 38(12):1327–1334. doi:10.​1007/​s40618-015-0376-6 CrossRefPubMed
25.
Zurück zum Zitat Sugitani I, Toda K, Yamada K et al (2010) Three distinctly different kinds of papillary thyroid microcarcinoma should be recognized: our treatment strategies and outcomes. World J Surg 34(6):1222–1231. doi:10.1007/s00268-009-0359-x CrossRefPubMed Sugitani I, Toda K, Yamada K et al (2010) Three distinctly different kinds of papillary thyroid microcarcinoma should be recognized: our treatment strategies and outcomes. World J Surg 34(6):1222–1231. doi:10.​1007/​s00268-009-0359-x CrossRefPubMed
27.
29.
Zurück zum Zitat Fukuoka O, Sugitani I, Ebina A et al (2016) Natural history of asymptomatic papillary thyroid microcarcinoma: time-dependent changes in calcification and vascularity during active surveillance. World J Surg 40(3):529–537. doi:10.1007/s00268-015-3349-1 CrossRefPubMed Fukuoka O, Sugitani I, Ebina A et al (2016) Natural history of asymptomatic papillary thyroid microcarcinoma: time-dependent changes in calcification and vascularity during active surveillance. World J Surg 40(3):529–537. doi:10.​1007/​s00268-015-3349-1 CrossRefPubMed
Metadaten
Titel
Impact of major different variants of papillary thyroid microcarcinoma on the clinicopathological characteristics: the study of 1041 cases
verfasst von
Jingtai Zhi
Jingzhu Zhao
Ming Gao
Yi Pan
Jianghua Wu
Yigong Li
Dapeng Li
Yang Yu
Xiangqian Zheng
Publikationsdatum
25.07.2017
Verlag
Springer Japan
Erschienen in
International Journal of Clinical Oncology / Ausgabe 1/2018
Print ISSN: 1341-9625
Elektronische ISSN: 1437-7772
DOI
https://doi.org/10.1007/s10147-017-1170-6

Weitere Artikel der Ausgabe 1/2018

International Journal of Clinical Oncology 1/2018 Zur Ausgabe

Update Onkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.